Abstract
The prognosis of patients with unresectabie or metastatic HER2 positive breast cancer has greatly improved after the introduction of new anti-HER2 drugs beyond trastuzumab. For most patients, a taxane combined with trastuzumab and pertuzumab in the first-line setting, followed by trastuzumab-emtansine in second line, should be considered the standard of the care today.
The treatment landscape of HER2-positive advanced disease is evolving constantly, several emerging anti-HER2 therapies are becoming available, including trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki [DS-8201a]). Trastuzumab deruxtecan (T-DXd) proved promising results in clinical studies DESTINY-BreastOI and Destiny-Breast03.
Here, we provide an overview of results of clinical studies with T-DXd and of the current and future management of HER2-positive advanced breast cancer.